Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection, the first market approved novel bispecific immune-oncology product by NMPA. Cadonilimab fully exploits the synergistic anti-tumor effect of two immune checkpoint inhibitors, PD-1 & CTLA-4, with significantly fewer side effects than the combination of two monoclonal antibodies with the relevant targets. At recent years, UP-Pharma has proudly provided bioanalytical supports to further expedite Akesobio ongoing clinical development studies in tumor treatment. The effective and fruitful collaboration helped the acceleration of drug development programs and bringing better medicine to patients.